Brought to you by 
Royalty Pharma acquires Humira revenue from CAT
29 May 2020
Executive Summary
Royalty Pharma (acquires royalty interests in late-stage and marketed biopharma products) has purchased royalty rights to Abbott Laboratories' rheumatoid arthritis drug Humira (adalimumab) from Cambridge Antibody Technologies (now part of AstraZeneca).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Royalty Pharma acquires Humira revenue from CAT
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice